VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms

• Main Authors: Grażyna Gadomska, Katarzyna Stankowska, Joanna Boinska, Robert Ślusarz, Marzena Tylicka, Małgorzata Michalska, Anna Jachalska, Danuta Rość
• Format: Article
• Language: English
• Published: MDPI AG 2017-01-01
• Series: Medicina
• Subjects: BCR-ABL-negative myeloproliferative neoplasm; VEGF-A; sVEGFR-1; sVEGFR-2
• Online Access: http://www.sciencedirect.com/science/article/pii/S1010660X17300046

Background and objective: Data from the literature indicate the relationship between the bone marrow microvessel density and the blood parameters of angiogenesis. The aim of this study was to evaluate selected parameters of angiogenesis (VEGF-A, sVEGFR-1, and sVEGFR-2) and their correlations with white blood cells, platelets, and red blood cells. Materials and methods: The study included 72 patients (mean age, 61.84 years) with myeloproliferative neoplasms (MPNs): essential thrombocythemia (ET) (n = 46), polycythemia vera (PV) (n = 19), and primary myelofibrosis (PMF) (n = 7). Serum VEGF-A, sVEGFR-1, and sVEGFR-2 were determined using the ELISA assay. Results: We observed a significantly higher level of VEGF-A and reduced concentrations of sVEGFR-1 and sVEGFR-2 in the whole group of patients with MPNs as compared to controls. Detailed analysis confirmed significantly higher level of VEGF-A and lower concentration of sVEGFR-2 in each subgroups of MPNs patients. However, sVEGFR-1 concentrations were significantly lower only in PV and ET patients. Conclusions: The study showed an increased level of VEGF-A, which may indicate the intensity of neoangiogenesis in the bone marrow. Decreased sVEGFR-1 and sVEGFR-2 in the blood of patients with MPNs may reflect consumption of these soluble receptors.